Even as a trial over alleged antitrust activity over drug patents gears up for March, drug makers AstraZeneca, Ranbaxy Pharmaceuticals, Teva Pharmaceuticals and Dr. Reddy’s Laboratories are hoping that the First Circuit will unwind a district judge’s decision to certify a class action of drug purchasers.

The plaintiffs are challenging the patent settlements between AstraZeneca and the three generic drug makers over the gastrointestinal drug Nexium on the grounds that the accords delayed the entry of generic versions of the drug until May of this year.